Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review.
Muhammad AsifMuhammad AmirAbrar HussainNiaz M AchakzaiPeter Natesan PushparajMahmood RasoolPublished in: Medicine (2022)
Severe acute respiratory syndrome (SARS) caused by a novel coronavirus-2 (CoV-2), also known as COVID-19, has spread rapidly worldwide since it is recognized as a public health emergency and has now been declared a pandemic on March 11, 2020, by the World Health Organization. The genome of SARS-CoV-2 comprises a single-stranded positive-sense RNA approximately 27 to 30 kb in size. The virus is transmitted through droplets from humans to humans. Infection with the SARS virus varies from asymptomatic to lethal, such as fever, cough, sore throat, and headache, but in severe cases, pneumonia and acute respiratory distress syndrome. Recently, no specific and effective treatment has been recommended for patients infected with the SARS virus. However, several options can be investigated to control SARS-CoV-2 infection, including monoclonal antibodies, interferons, therapeutic vaccines, and molecular-based targeted drugs. In the current review, we focus on tyrosine kinase inhibitor management and their protective role in SARS-CoV-2 patients with chronic myelogenous leukemia.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- acute respiratory distress syndrome
- public health
- coronavirus disease
- chronic myeloid leukemia
- end stage renal disease
- extracorporeal membrane oxygenation
- ejection fraction
- chronic kidney disease
- mechanical ventilation
- newly diagnosed
- emergency department
- healthcare
- acute myeloid leukemia
- prognostic factors
- gene expression
- early onset
- binding protein
- drug delivery
- dna methylation
- mass spectrometry
- global health
- combination therapy
- nucleic acid